Zion Market Research has published a new report titled “Hemostasis Diagnostics Market by Product Type (Laboratory Systems, Consumables, and Point-of-Care Testing Systems), by Test Type (Prothrombin Test Time (PT), Activated Partial Thromboplastin Time (APTT), Fibrinogen Degradation Products (FDP), Activated Clotting Time, Platelet Aggregation Test, and D Dimer), and by End-User (Hospital & Clinics, Independent Diagnostic Laboratories, and Home Care Settings): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017—2024”. According to the report, the global hemostasis diagnostics market was valued at approximately USD 4.2 billion in 2017 and is expected to generate revenue of around USD 7.3 billion by 2024, at a CAGR of around 8.1% between 2018 and 2024.
Hemostasis is a process of slowing down or stopping bleeding from damaged blood vessels during this process the blood changes from liquid to a gelatinous state. It is the first stage of wound healing. Hemostasis devices are used to detect hemostatic defects that can lead to excessive bleeding. Thus, to achieve hemostasis during emergencies, various chemical agents are used to stop bleeding as the hemorrhage can be life-threatening for the patient.
The major factor that is likely to drive the hemostasis diagnostics market over the forecast timeframe is the increased prevalence of hemostasis disorders. The increased occurrence of genetically inherited diseases is likely to fuel the hemostasis diagnostics market in the foreseeable future. Moreover, high investment in research and development is projected to drive the development of new and advanced products over the estimated years. However, the high cost of advanced hemostasis devices and stringent regulatory policies regarding the approval of these diagnostics might hamper the hemostasis diagnostics market in the future.
The hemostasis diagnostics market is classified into product type, end user, and test type. By product type, the hemostasis diagnostics market is segmented into laboratory systems, consumables, and point-of-care testing systems. Laboratory systems are expected to dominate the hemostasis diagnostic market in the future. By test type, the hemostasis diagnostics market is segmented into prothrombin test time (PT), activated partial thromboplastin time (APTT), fibrinogen degradation products (FDP), activated clotting time, platelet aggregation test, and D dimer. Prothrombin test time is expected to dominate the market over the estimated time period. By end-user, the hemostasis diagnostics market is segmented into hospital and clinics, independent diagnostic laboratories, and home care settings. Hospitals and clinics are likely to dominate the market over the forecast time period.
By region, the hemostasis diagnostics market includes North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is expected to dominate the global hemostasis diagnostics market over the forecast timeline, owing to the presence of developed countries, such as the U.S. and Canada. The European market is expected to closely follow the North American market in terms of revenue. The Asia Pacific is likely to register the fastest rate of growth over the forecast time period.
The major players of the global hemostasis diagnostics market include Siemens Healthineers, Abbott Laboratories, Instrumentation Laboratory, Thermo Fisher Scientific Inc., Alere Inc., Nihon Kohden Corporation, Sysmex Corporation, Danaher Corporation, F. Hoffmann-La Roche Ltd., and Grifols S.A.
This report segments the global hemostasis diagnostics market into:
Global Hemostasis Diagnostics Market: Product Type Analysis
Global Hemostasis Diagnostics Market: Test Type Analysis
Global Hemostasis Diagnostics Market: End-User Analysis
Global Hemostasis Diagnostics Market: Regional Analysis
You can Buy This Report from Here @https://www.zionmarketresearch.com/buynow/su/hemostasis-diagnostics-market/news